150 related articles for article (PubMed ID: 31239782)
1. Gephyrin suppresses lung squamous cell carcinoma development by reducing mTOR pathway activation.
Zhang X; Cheng D; Liu Y; Wu Y; He Z
Cancer Manag Res; 2019; 11():5333-5341. PubMed ID: 31239782
[No Abstract] [Full Text] [Related]
2. Downregulation of VRK1 Inhibits Progression of Lung Squamous Cell Carcinoma through DNA Damage.
Du N; Zhang B; Zhang Y
Can Respir J; 2023; 2023():4533504. PubMed ID: 37547297
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-mediated YTHDF2 overexpression promotes lung squamous cell carcinoma progression by activation of the mTOR/AKT axis.
Xu P; Hu K; Zhang P; Sun ZG; Zhang N
Cancer Cell Int; 2022 Jan; 22(1):13. PubMed ID: 34996459
[TBL] [Abstract][Full Text] [Related]
4. PTBP3 regulates proliferation of lung squamous cell carcinoma cells via CDC25A-mediated cell cycle progression.
Chen Y; Ji Y; Liu S; Liu Y; Feng W; Jin L
Cancer Cell Int; 2022 Jan; 22(1):19. PubMed ID: 35016691
[TBL] [Abstract][Full Text] [Related]
5. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
6. Chromobox Homologue 7 Acts as a Tumor Suppressor in Both Lung Adenocarcinoma and Lung Squamous Cell Carcinoma via Inhibiting ERK/MAPK Signaling Pathway.
Huang J; Zhang W; Lin D; Lian L; Hong W; Xu Z
Evid Based Complement Alternat Med; 2022; 2022():4952185. PubMed ID: 35646140
[TBL] [Abstract][Full Text] [Related]
7. High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma.
Li L; Liu YD; Zhan YT; Zhu YH; Li Y; Xie D; Guan XY
Thorac Cancer; 2018 Jul; 9(7):775-784. PubMed ID: 29722145
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of IL-6R mRNA in lung adenocarcinoma and squamous cell carcinoma.
Xu B; Chen Q; Yue C; Lan L; Jiang J; Shen Y; Lu B
Oncol Lett; 2018 Sep; 16(3):2935-2948. PubMed ID: 30127882
[TBL] [Abstract][Full Text] [Related]
9. Skp2 expression has different clinicopathological and prognostic implications in lung adenocarcinoma and squamous cell carcinoma.
Zhong K; Yang F; Han Q; Chen J; Wang J
Oncol Lett; 2018 Sep; 16(3):2873-2880. PubMed ID: 30127874
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
11. Calponin 3 suppresses proliferation, migration and invasion of non-small cell lung cancer cells.
Yang C; Zhu S; Feng W; Chen X
Oncol Lett; 2021 Aug; 22(2):634. PubMed ID: 34267826
[TBL] [Abstract][Full Text] [Related]
12. c-Rel is a Novel Oncogene in Lung Squamous Cell Carcinoma Regulating Cell Proliferation and Migration.
Luo R; Liu Q; Hu Z; Dai W; Huang S; Xie J; Wei S; Lin C
J Cancer; 2024; 15(8):2329-2339. PubMed ID: 38495491
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic loss of putative tumor suppressor SFRP3 correlates with poor prognosis of lung adenocarcinoma patients.
Schlensog M; Magnus L; Heide T; Eschenbruch J; Steib F; Tator M; Kloten V; Rose M; Noetzel E; Gaisa NT; Knüchel R; Dahl E
Epigenetics; 2018; 13(3):214-227. PubMed ID: 27623992
[TBL] [Abstract][Full Text] [Related]
14. Identification of the prognostic and therapeutic values of cyclin E1 (
Ullah MA; Farzana M; Islam MS; Moni R; Zohora US; Rahman MS
Heliyon; 2022 Sep; 8(9):e10367. PubMed ID: 36091953
[TBL] [Abstract][Full Text] [Related]
15. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
16. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
17. High ECT2 expression is an independent prognostic factor for poor overall survival and recurrence-free survival in non-small cell lung adenocarcinoma.
Zhou S; Wang P; Su X; Chen J; Chen H; Yang H; Fang A; Xie L; Yao Y; Yang J
PLoS One; 2017; 12(10):e0187356. PubMed ID: 29088286
[TBL] [Abstract][Full Text] [Related]
18. Telomere-associated genes and telomeric lncRNAs are biomarker candidates in lung squamous cell carcinoma (LUSC).
Storti CB; de Oliveira RA; de Carvalho M; Hasimoto EN; Cataneo DC; Cataneo AJM; De Faveri J; Vasconcelos EJR; Dos Reis PP; Cano MIN
Exp Mol Pathol; 2020 Feb; 112():104354. PubMed ID: 31837325
[TBL] [Abstract][Full Text] [Related]
19. CD73 Severed as a Potential Prognostic Marker and Promote Lung Cancer Cells Migration
Gao ZW; Liu C; Yang L; Chen HC; Yang LF; Zhang HZ; Dong K
Front Genet; 2021; 12():728200. PubMed ID: 34868205
[TBL] [Abstract][Full Text] [Related]
20. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
